As we continue to develop a better understanding of the underlying biology for neurological diseases such as Alzheimer’s, researchers are seeking biomarkers that may help in numerous ways. From early diagnosis or disease progression, to surrogate efficacy markers for treatments, biomarkers may be the key to better studying these diseases. The challenge is determining which markers are appropriate and sorting the signals from the noise. Rembach et. al recently published a review looking at blood-based markers for AD, which offer more accessible targets than those found in CSF.